Search Orphan Drug Designations and Approvals
-
Generic Name: | rituximab | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Rituxan | ||||||||||||||||
Date Designated: | 01/29/2004 | ||||||||||||||||
Orphan Designation: | Treatment of chronic lymphocytic leukemia | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Genentech, Inc. 1DNA Way MS 241A South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | rituximab |
---|---|---|
Trade Name: | Rituxan | |
Marketing Approval Date: | 02/18/2010 | |
Approved Labeled Indication: | Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide | |
Exclusivity End Date: | 02/18/2017 | |
Exclusivity Protected Indication* : | ||
-